CelLBxHealth plc (ANPCF)
| Market Cap | 14.35M -62.4% |
| Revenue (ttm) | 3.60M +29.6% |
| Net Income | -21.62M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,000 |
| Average Volume | 15,016 |
| Open | 0.0137 |
| Previous Close | n/a |
| Day's Range | 0.0127 - 0.0137 |
| 52-Week Range | 0.01266 - 0.1061 |
| Beta | 0.19 |
| RSI | 33.78 |
| Earnings Date | Jun 1, 2026 |
About CelLBxHealth
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic... [Read more]
Financial Performance
In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.
Financial numbers in GBP Financial StatementsNews
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample GUILDFORD, ...